Molecular approaches towards characterization, monitoring and targeting of viral-associated hematological malignancies

References

• Abruzzo LV, Rosales CM, Medeiros LJ et al. Epstein–Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am. J. Surg. Pathol.26(5), 630–636 (2002).
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Otteman LA, White WL. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. N. Engl. J. Med.349(26), 2570–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Ahmed N, Heslop HE. Viral lymphomagenesis. Curr. Opin. Hematol.13(4), 254–259 (2006).
   PubMed Web of Science ®Google Scholar
• Thompson MP, Kurzrock R. Epstein–Barr virus and cancer. Clin. Cancer Res.10(3), 803–821 (2004).
   PubMed Web of Science ®Google Scholar
• Schelcher C, Valencia S, Delecluse HJ, Hicks M, Sinclair AJ. Mutation of a single amino acid residue in the basic region of the Epstein–Barr virus (EBV) lytic cycle switch protein Zta (BZLF1) prevents reactivation of EBV from latency. J. Virol.79(21), 13822–13828 (2005).
   PubMed Web of Science ®Google Scholar
• Koehne G, Smith KM, Ferguson TL et al. Quantitation, selection, and functional characterization of Epstein–Barr virus-specific and alloreactive T cells detected by intracellular interferon-γ production and growth of cytotoxic precursors. Blood99(5), 1730–1740 (2002).
   PubMed Web of Science ®Google Scholar
• Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A. Epstein–Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J. Virol.64(9), 4084–4092 (1990).
   PubMed Web of Science ®Google Scholar
• Cohen JI, Picchio GR, Mosier DE. Epstein–Barr virus nuclear protein 2 is a critical determinant for tumor growth in SCID mice and for transformation in vitro. J. Virol.66(12), 7555–7559 (1992).
   PubMed Web of Science ®Google Scholar
• Kaye KM, Izumi KM, Li H et al. An Epstein–Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation. J. Virol.73(12), 10525–10530 (1999).
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Tahara H, Ide T, Furuichi Y. Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein–Barr virus. Cancer Res.64(10), 3361–3364 (2004).
   PubMed Web of Science ®Google Scholar
• Altmann M, Hammerschmidt W. Epstein–Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol.3(12), E404 (2005).
   PubMedGoogle Scholar
• Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein–Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell80(3), 389–399 (1995).
   PubMed Web of Science ®Google Scholar
• Brinkmann MM, Schulz TF. Regulation of intracellular signalling by the terminal membrane proteins of members of the Gammaherpesvirinae. J. Gen. Virol.87(Pt 5), 1047–1074 (2006).
   PubMed Web of Science ®Google Scholar
• Middleton T, Sugden B. Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein–Barr virus replication protein EBNA1. J. Virol.68(6), 4067–4071 (1994).
   PubMed Web of Science ®Google Scholar
• Niller HH, Salamon D, Banati F, Schwarzmann F, Wolf H, Minarovits J. The LCR of EBV makes Burkitt’s lymphoma endemic. Trends Microbiol.12(11), 495–499 (2004).
   PubMed Web of Science ®Google Scholar
• Lin J, Johannsen E, Robertson E, Kieff E. Epstein–Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2. J. Virol.76(1), 232–242 (2002).
   PubMed Web of Science ®Google Scholar
• Kashuba E, Mattsson K, Pokrovskaja K et al. EBV-encoded EBNA-5 associates with P14ARF in extranucleolar inclusions and prolongs the survival of P14ARF-expressing cells. Int. J. Cancer105(5), 644–653 (2003).
   PubMed Web of Science ®Google Scholar
• Casola S, Otipoby KL, Alimzhanov M et al. B cell receptor signal strength determines B cell fate. Nat. Immunol.5(3), 317–327 (2004).
   PubMed Web of Science ®Google Scholar
• Fukuda M, Longnecker R. Epstein–Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation. J. Virol.79(13), 8655–8660 (2005).
   PubMed Web of Science ®Google Scholar
• Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of “crippled” germinal center B cells from apoptosis by Epstein–Barr virus. Blood106(13), 4339–4344 (2005).
   PubMed Web of Science ®Google Scholar
• Nanbo A, Yoshiyama H, Takada K. Epstein–Barr virus-encoded poly(A)- RNA confers resistance to apoptosis mediated through Fas by blocking the PKR pathway in human epithelial intestine 407 cells. J. Virol.79(19), 12280–12285 (2005).
   PubMed Web of Science ®Google Scholar
• Clybouw C, McHichi B, Mouhamad S et al. EBV infection of human B lymphocytes leads to down-regulation of Bim expression: relationship to resistance to apoptosis. J. Immunol.175(5), 2968–2973 (2005).
   PubMed Web of Science ®Google Scholar
• Thornburg NJ, Kulwichit W, Edwards RH, Shair KH, Bendt KM, Raab-Traub N. LMP1 signaling and activation of NF-κB in LMP1 transgenic mice. Oncogene25(2), 288–297 (2006).
   PubMed Web of Science ®Google Scholar
• Capello D, Rossi D, Gaidano G. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol. Oncol.23(2), 61–67 (2005).
   PubMed Web of Science ®Google Scholar
• Bechtel D, Kurth J, Unkel C, Kuppers R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood106(13), 4345–4350 (2005).
   PubMed Web of Science ®Google Scholar
• Kim LH, Peh SC, Poppema S. Expression of retinoblastoma protein and P16 proteins in classic Hodgkin lymphoma: relationship with expression of p53 and presence of Epstein–Barr virus in the regulation of cell growth and death. Hum. Pathol.37(1), 92–100 (2006).
   PubMed Web of Science ®Google Scholar
• Brink AA, Dukers DF, van den Brule AJ et al. Presence of Epstein–Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. J. Clin. Pathol.50(11), 911–918 (1997).
   PubMed Web of Science ®Google Scholar
• Yin CC, Medeiros LJ, Abruzzo LV, Jones D, Farhood AI, Thomazy VA. EBV-associated B- and T-cell posttransplant lymphoproliferative disorders following primary EBV infection in a kidney transplant recipient. Am. J. Clin. Pathol.123(2), 222–228 (2005).
   PubMed Web of Science ®Google Scholar
• Hsu JL, Glaser SL. Epstein–Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit. Rev. Oncol. Hematol.34(1), 27–53 (2000).
   PubMed Web of Science ®Google Scholar
• Chadburn A, Cesarman E, Knowles DM. Molecular pathology of posttransplantation lymphoproliferative disorders. Semin. Diagn. Pathol.14(1), 15–26 (1997).
   PubMed Web of Science ®Google Scholar
• Sharma V. Current perspectives on cytokines for anti-retroviral therapy in AIDS related B-cell lymphomas. Curr. Drug Targets Infect. Disord.3(2), 137–149 (2003).
   PubMedGoogle Scholar
• Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br. J. Haematol.130(5), 662–670 (2005).
   PubMed Web of Science ®Google Scholar
• Oyama T, Ichimura K, Suzuki R et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am. J. Surg. Pathol.27(1), 16–26 (2003).
   PubMed Web of Science ®Google Scholar
• Tai YC, Kim LH, Peh SC. High frequency of EBV association and 30-bp deletion in the LMP-1 gene in CD56 lymphomas of the upper aerodigestive tract. Pathol. Int.54(3), 158–166 (2004).
   PubMed Web of Science ®Google Scholar
• Nagato T, Kobayashi H, Kishibe K et al. Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients. Clin. Cancer Res.11(23), 8250–8257 (2005).
   PubMed Web of Science ®Google Scholar
• Jarrett RF. Risk factors for Hodgkin’s lymphoma by EBV status and significance of detection of EBV genomes in serum of patients with EBV-associated Hodgkin’s lymphoma. Leuk. Lymphoma44(Suppl. 3), S27–S32 (2003).
   PubMed Web of Science ®Google Scholar
• Chang KC, Khen NT, Jones D, Su IJ. Epstein–Barr virus is associated with all histological subtypes of Hodgkin lymphoma in Vietnamese children with special emphasis on the entity of lymphocyte predominance subtype. Hum. Pathol.36(7), 747–755 (2005).
   PubMed Web of Science ®Google Scholar
• Berger C, Day P, Meier G, Zingg W, Bossart W, Nadal D. Dynamics of Epstein–Barr virus DNA levels in serum during EBV-associated disease. J. Med. Virol.64(4), 505–512 (2001).
   PubMed Web of Science ®Google Scholar
• Ivers LC, Kim AY, Sax PE. Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein–Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin. Infect. Dis.38(11), 1629–1632 (2004).
   PubMed Web of Science ®Google Scholar
• Niedobitek G, Herbst H. In situ detection of Epstein–Barr virus and phenotype determination of EBV-infected cells. Methods Mol. Biol.326, 115–137 (2006).
   PubMedGoogle Scholar
• Hassan R, White LR, Stefanoff CG et al. Epstein–Barr Virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt’s lymphoma. Diagn. Pathol.1, 17 (2006).
   PubMed Web of Science ®Google Scholar
• Le QT, Jones CD, Yau TK et al. A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin. Cancer Res.11(16), 5700–5707 (2005).
   PubMed Web of Science ®Google Scholar
• Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a real-time quantitative assay for detection of Epstein–Barr virus. J. Clin. Microbiol.38(2), 712–715 (2000).
   PubMed Web of Science ®Google Scholar
• Stevens SJ, Verschuuren EA, Pronk I et al. Frequent monitoring of Epstein–Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood97(5), 1165–1171 (2001).
   PubMed Web of Science ®Google Scholar
• Stevens SJ, Pronk I, Middeldorp JM. Toward standardization of Epstein–Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J. Clin. Microbiol.39(4), 1211–1216 (2001).
   PubMed Web of Science ®Google Scholar
• van Esser JW, van der Holt B, Meijer E et al. Epstein–Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. Blood98(4), 972–978 (2001).
   PubMed Web of Science ®Google Scholar
• Meij P, van Esser JW, Niesters HG et al. Impaired recovery of Epstein–Barr virus (EBV) – specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood101(11), 4290–4297 (2003).
   PubMed Web of Science ®Google Scholar
• Lin JC, Wang WY, Chen KY et al. Quantification of plasma Epstein–Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N. Engl. J. Med.350(24), 2461–2470 (2004).
   PubMed Web of Science ®Google Scholar
• Fan H, Kim SC, Chima CO et al. Epstein–Barr viral load as a marker of lymphoma in AIDS patients. J. Med. Virol.75(1), 59–69 (2005).
   PubMed Web of Science ®Google Scholar
• Chang Y, Cesarman E, Pessin MS et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science266(5192), 1865–1869 (1994).
   PubMed Web of Science ®Google Scholar
• Huang YQ, Li JJ, Zhang WG, Feiner D, Friedman-Kien AE. Transcription of human herpesvirus-like agent (HHV-8) in Kaposi’s sarcoma. J. Clin. Invest.97(12), 2803–2806 (1996).
   PubMed Web of Science ®Google Scholar
• Wheat WH, Cool CD, Morimoto Y et al. Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency. J. Exp. Med.202(4), 479–484 (2005).
   PubMed Web of Science ®Google Scholar
• Russo JJ, Bohenzky RA, Chien MC et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl Acad. Sci. USA93(25), 14862–14867 (1996).
   PubMed Web of Science ®Google Scholar
• Means RE, Choi JK, Nakamura H, Chung YH, Ishido S, Jung JU. Immune evasion strategies of Kaposi’s sarcoma-associated herpesvirus. Curr. Top. Microbiol. Immunol.269, 187–201 (2002).
   PubMed Web of Science ®Google Scholar
• Ottinger M, Christalla T, Nathan K, Brinkmann MM, Viejo-Borbolla A, Schulz TF. The Kaposi’s sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3- induced G1 cell cycle arrest. J. Virol.80(21), 10772–10786 (2006).
   PubMed Web of Science ®Google Scholar
• Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science284(5414), 641–644 (1999).
   PubMed Web of Science ®Google Scholar
• Bais C, Van Geelen A, Eroles P et al. Kaposi’s sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell3(2), 131–143 (2003).
   PubMed Web of Science ®Google Scholar
• Prakash O, Tang ZY, Peng X et al. Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene. J. Natl Cancer Inst.94(12), 926–935 (2002).
   PubMedGoogle Scholar
• Oksenhendler E, Boulanger E, Galicier L et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood99(7), 2331–2336 (2002).
   PubMed Web of Science ®Google Scholar
• Amin HM, Medeiros LJ, Manning JT, Jones D. Dissolution of the lymphoid follicle is a feature of the HHV8+ variant of plasma cell Castleman’s disease. Am. J. Surg. Pathol.27(1), 91–100 (2003).
   PubMed Web of Science ®Google Scholar
• An J, Lichtenstein AK, Brent G, Rettig MB. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. Blood99(2), 649–654 (2002).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood106(8), 2627–2632 (2005).
   PubMed Web of Science ®Google Scholar
• Knowles DM, Inghirami G, Ubriaco A, Dalla-Favera R. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein–Barr virus. Blood73(3), 792–799 (1989).
   PubMed Web of Science ®Google Scholar
• Nador RG, Cesarman E, Chadburn A et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood88(2), 645–656 (1996).
   PubMed Web of Science ®Google Scholar
• Klein U, Gloghini A, Gaidano G et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood101(10), 4115–4121 (2003).
   PubMed Web of Science ®Google Scholar
• Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST. High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia19(5), 851–855 (2005).
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Vaccher E, Marchetti G, Gaidano G, Tirelli U. KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype. J. Clin. Pathol.58(10), 1039–1045 (2005).
   PubMed Web of Science ®Google Scholar
• Engels EA, Pittaluga S, Whitby D et al. Immunoblastic lymphoma in persons with AIDS-associated Kaposi’s sarcoma: a role for Kaposi’s sarcoma-associated herpesvirus. Mod. Pathol.16(5), 424–429 (2003).
   PubMed Web of Science ®Google Scholar
• Chen L, Lagunoff M. Establishment and maintenance of Kaposi’s sarcoma-associated herpesvirus latency in B cells. J. Virol.79(22), 14383–14391 (2005).
   PubMed Web of Science ®Google Scholar
• Si H, Robertson ES. Kaposi’s sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J. Virol.80(2), 697–709 (2006).
   PubMed Web of Science ®Google Scholar
• Jones D, Ballestas ME, Kaye KM et al. Primary-effusion lymphoma and Kaposi’s sarcoma in a cardiac-transplant recipient. N. Engl. J. Med.339(7), 444–449 (1998).
   PubMed Web of Science ®Google Scholar
• Wilson KS, McKenna RW, Kroft SH, Dawson DB, Ansari Q, Schneider NR. Primary effusion lymphomas exhibit complex and recurrent cytogenetic abnormalities. Br. J. Haematol.116(1), 113–121 (2002).
   PubMed Web of Science ®Google Scholar
• Lan K, Kuppers DA, Robertson ES. Kaposi’s sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jκ, the major downstream effector of the Notch signaling pathway. J. Virol.79(6), 3468–3478 (2005).
   PubMed Web of Science ®Google Scholar
• Muromoto R, Okabe K, Fujimuro M et al. Physical and functional interactions between STAT3 and Kaposi’s sarcoma-associated herpesvirus-encoded LANA. FEBS Lett.580(1), 93–98 (2006).
   PubMed Web of Science ®Google Scholar
• Staskus KA, Sun R, Miller G et al. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. J. Virol.73(5), 4181–4187 (1999).
   PubMed Web of Science ®Google Scholar
• Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M. A prognostic index for AIDS-associated Kaposi’s sarcoma in the era of highly active antiretroviral therapy. Lancet367(9521), 1495–1502 (2006).
   PubMed Web of Science ®Google Scholar
• Boulanger E, Gerard L, Gabarre J et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J. Clin. Oncol.23(19), 4372–4380 (2005).
   PubMed Web of Science ®Google Scholar
• Simonelli C, Tedeschi R, Gloghini A et al. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy. Clin. Infect. Dis.40(7), 1022–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Engels EA, Biggar RJ, Marshall VA et al. Detection and quantification of Kaposi’s sarcoma-associated herpesvirus to predict AIDS-associated Kaposi’s sarcoma. AIDS17(12), 1847–1851 (2003).
   PubMed Web of Science ®Google Scholar
• Rollison DE, Helzlsouer KJ, Halsey NA, Shah KV, Viscidi RP. Markers of past infection with simian virus 40 (SV40) and risk of incident non-Hodgkin lymphoma in a Maryland cohort. Cancer Epidemiol. Biomarkers Prev.14(6), 1448–1452 (2005).
   PubMed Web of Science ®Google Scholar
• Shivapurkar N, Harada K, Reddy J et al. Presence of simian virus 40 DNA sequences in human lymphomas. Lancet359(9309), 851–852 (2002).
   PubMed Web of Science ®Google Scholar
• Butel JS, Vilchez RA, Jorgensen JL, Kozinetz CA. Association between SV40 and non-Hodgkin’s lymphoma. Leuk. Lymphoma44(Suppl. 3), S33–S39 (2003).
   PubMed Web of Science ®Google Scholar
• Nakatsuka S, Liu A, Dong Z et al. Simian virus 40 sequences in malignant lymphomas in Japan. Cancer Res.63(22), 7606–7608 (2003).
   PubMed Web of Science ®Google Scholar
• Vilchez RA, Lopez-Terrada D, Middleton JR et al. Simian virus 40 tumor antigen expression and immunophenotypic profile of AIDS-related non-Hodgkin’s lymphoma. Virology342(1), 38–46 (2005).
   PubMed Web of Science ®Google Scholar
• Capello D, Rossi D, Gaudino G, Carbone A, Gaidano G. Simian virus 40 infection in lymphoproliferative disorders. Lancet361(9351), 88–89 (2003).
   PubMed Web of Science ®Google Scholar
• Schuler F, Dolken SC, Hirt C et al. No evidence for simian virus 40 DNA sequences in malignant non-Hodgkin lymphomas. Int. J. Cancer118(2), 498–504 (2006).
   PubMed Web of Science ®Google Scholar
• MacKenzie J, Wilson KS, Perry J, Gallagher A, Jarrett RF. Association between simian virus 40 DNA and lymphoma in the United Kingdom. J. Natl Cancer Inst.95(13), 1001–1003 (2003).
   PubMed Web of Science ®Google Scholar
• Brousset P, de Araujo V, Gascoyne RD. Immunohistochemical investigation of SV40 large T antigen in Hodgkin and non-Hodgkin’s lymphoma. Int. J. Cancer112(3), 533–535 (2004).
   PubMed Web of Science ®Google Scholar
• Engels EA, Chen J, Hartge P et al. Antibody responses to simian virus 40 T antigen: a case-control study of non-Hodgkin lymphoma. Cancer Epidemiol. Biomarkers Prev.14(2), 521–524 (2005).
   PubMed Web of Science ®Google Scholar
• Rollison DE, Page WF, Crawford H et al. Case-control study of cancer among US Army veterans exposed to simian virus 40-contaminated adenovirus vaccine. Am. J. Epidemiol.160(4), 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• Engels EA. Does simian virus 40 cause non-Hodgkin lymphoma? A review of the laboratory and epidemiological evidence. Cancer Invest.23(6), 529–536 (2005).
   PubMed Web of Science ®Google Scholar
• McNees AL, White ZS, Zanwar P, Vilchez RA, Butel JS. Specific and quantitative detection of human polyomaviruses BKV, JCV, and SV40 by real time PCR. J. Clin. Virol.34(1), 52–62 (2005).
   PubMed Web of Science ®Google Scholar
• Li X, Liu X, Li CY et al. Recombinant adeno-associated virus mediated RNA interference inhibits metastasis of nasopharyngeal cancer cells in vivo and in vitro by suppression of Epstein–Barr virus encoded LMP-1. Int. J. Oncol.29(3), 595–603 (2006).
   PubMed Web of Science ®Google Scholar
• Montaner S, Sodhi A, Ramsdell AK et al. The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi’s sarcoma. Cancer Res.66(1), 168–174 (2006).
   PubMed Web of Science ®Google Scholar
• Corte-Real S, Collins C, Aires da Silva F et al. Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells. Blood106(12), 3797–3802 (2005).
   PubMed Web of Science ®Google Scholar
• Klass CM, Krug LT, Pozharskaya VP, Offermann MK. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood105(10), 4028–4034 (2005).
   PubMed Web of Science ®Google Scholar
• Bollard CM, Aguilar L, Straathof KC et al. Cytotoxic T lymphocyte therapy for Epstein–Barr virus+ Hodgkin’s disease. J. Exp. Med.200(12), 1623–1633 (2004).
   PubMed Web of Science ®Google Scholar